Vivos (RDGL) Net Cash Flow Growth (3y) (2013 - 2025)
Vivos (RDGL) Net Cash Flow Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.38 Bn | 176.08 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 129.56 Bn | 126.68 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 109.00 Bn | 99.78 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 68.59 Bn | 67.13 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 47.58 Bn | 43.90 Bn | 1.29 Bn | -87.88% |
| 6 | Dexcom | 28.65 Bn | 27.53 Bn | 750.30 Mn | 129.29% |
| 7 | GE HealthCare Technologies | 28.55 Bn | 26.27 Bn | 1.98 Bn | -65.12% |
| 8 | Smith & Nephew | 27.05 Bn | 26.48 Bn | - | - |
| 9 | Koninklijke Philips | 25.59 Bn | 22.46 Bn | 2.07 Bn | -48.90% |
| 10 | Vivos | 27.57 Mn | 26.01 Mn | -3,105.00 | -24.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24.26% |
| Sep 30, 2025 | -17.45% |
| Jun 30, 2025 | -52.30% |
| Mar 31, 2025 | 67.97% |
| Dec 31, 2024 | 66.47% |
| Sep 30, 2024 | -41.66% |
| Jun 30, 2024 | 44.52% |
| Mar 31, 2024 | -28.82% |
| Dec 31, 2023 | -60.34% |
| Sep 30, 2023 | 3.24% |
| Jun 30, 2023 | -48.72% |
| Mar 31, 2023 | -167.28% |
| Dec 31, 2022 | -26.80% |
| Sep 30, 2022 | -57.22% |
| Jun 30, 2022 | -72.59% |
| Mar 31, 2022 | -132.62% |
| Dec 31, 2021 | -314.57% |
| Jun 30, 2021 | -2,689.18% |
| Mar 31, 2021 | 480.61% |
| Dec 31, 2020 | 305.01% |